Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.6% – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) was up 6.6% on Thursday . The stock traded as high as $31.02 and last traded at $32.1220. Approximately 184,252 shares were traded during trading, a decline of 87% from the average daily volume of 1,370,198 shares. The stock had previously closed at $30.12.

Analysts Set New Price Targets

CAPR has been the topic of several recent research reports. Maxim Group boosted their price objective on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday, March 13th. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a report on Tuesday, March 10th. UBS Group set a $50.00 price objective on shares of Capricor Therapeutics in a research report on Monday, December 15th. Finally, Wall Street Zen lowered Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.09.

Capricor Therapeutics Stock Up 5.3%

The business’s fifty day moving average is $27.04 and its 200 day moving average is $18.74. The stock has a market cap of $1.82 billion, a PE ratio of -14.06 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). As a group, analysts predict that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Insider Activity

In related news, Director Karimah Es Sabar sold 53,735 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $31.03, for a total value of $1,667,397.05. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the transaction, the chief financial officer owned 8,223 shares of the company’s stock, valued at approximately $247,758.99. The trade was a 75.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 140,000 shares of company stock worth $4,269,012 over the last quarter. Insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CAPR. Suvretta Capital Management LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter valued at $51,533,000. Tang Capital Management LLC purchased a new position in Capricor Therapeutics in the 4th quarter valued at about $49,062,000. RA Capital Management L.P. acquired a new stake in shares of Capricor Therapeutics during the 4th quarter worth about $43,516,000. Darwin Global Management Ltd. purchased a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $23,168,000. Finally, SB Capital Management Inc purchased a new stake in shares of Capricor Therapeutics during the fourth quarter worth about $11,544,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.